Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
bone metastasis
bone-modifying agent
castration-resistant prostate cancer
radium-223
symptomatic skeletal event
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
25
05
2023
accepted:
13
07
2023
medline:
2
11
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
Radium-223 (Ra-223) dichloride therapy increases overall survival and delays time to the first symptomatic skeletal event (SSE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Bone-modifying agents (BMA) reduce SSE in patients with bone metastasis, but there is little information on their use with Ra-223. This study aimed to investigate the effect of BMA on SSE in patients with bone metastatic CRPC treated with Ra-223 in real-world practice. We included 73 patients treated with Ra-223 from 10 institutions in Japan. Time to the first SSE was estimated using the Kaplan-Meier method and compared between groups using the log-rank test. We used univariate analysis to ascertain the association between variables and SSE. During a median follow-up of 12.7 months (interquartile range, 7-21.7), 12 (16.4%) patients presented SSE. Age and BMA use were different between men with and without SSE. The 1-year SSE-free survival rate from Ra-223 treatment initiation was 82.4% (95% CI, 69.4%-90.2%). BMA use was associated with favorable SSE-free survival (hazard risk, 0.23; 95% confidence interval, 0.061-0.85; p = 0.027). Two (4.7%) and seven (23.3%) patients presented symptomatic pathological bone fracture in groups with and without BMA use, respectively (p = 0.017). This study stresses the importance of BMA use in patients with CRPC and bone metastases in Ra-223 treatment.
Substances chimiques
Radium-223
8BR2SOL3L1
radium Ra 223 dichloride
RJ00KV3VTG
Radium
W90AYD6R3Q
Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1029-1034Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 The Japanese Urological Association.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Cornford P, van den Bergh RCN, Briers E, van den Broeck T, Cumberbatch MG, de Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263-282.
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242-245.
Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23(13):2918-2925.
Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol. 2014;11(6):335-345.
Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-1664.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Zoledronic acid prostate cancer study group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-882.
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-223.
Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397-1406.
Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27(5):868-874.
Kawahara T, Miyoshi Y, Ninomiya S, Sato M, Takeshima T, Hasumi H, et al. Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: a large database study. Int J Urol. 2022;29(9):1079-1084.
Hashimoto K, Miyoshi Y, Shindo T, Hori M, Tsuboi Y, Kobayashi K, et al. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer. Cancer Med. 2020;9(22):8579-8588.
Yamamoto Y, Okuda Y, Kanaki T, Tanaka R, Nagahara A, Nakai Y, et al. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. Int J Clin Oncol. 2021;26(1):192-198.
Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, et al. Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: a real-world multicenter retrospective study. Urol Oncol. 2022;40(2):64.e1-64.e8.
Matsumoto T, Hori Y, Shiota M, Blas L, Nakamura M, Seki N, et al. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: a multi-institutional study. Int J Urol. 2023;30(2):139-146.
Badrising SK, Louhanepessy RD, van der Noort V, Coenen JL, Hamberg P, Beeker A, et al. A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. Int J Cancer. 2020;147(4):1143-1151.
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408-419.
Gillessen S, Choudhury A, Rodriguez-Vida A, Nole F, Gallardo Diaz E, Roumeguere TA, et al. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: an updated safety analysis. J Clin Oncol. 2021;39(Suppl 15):5002.